English 
Curadh MTR Inc. and Alpha Fusion, Inc. are set to showcase their progress in radiopharmaceutical development at the 4th Targeted Radiopharmaceuticals Summit US, scheduled later this month in San Diego. The two companies recently announced plans to enter a strategic partnership, which includes forming a joint venture to drive the global advancement of Astatine-211 (At-211)-based radiopharmaceuticals for the treatment of various cancers.
Dr. Alison Armour, Chief Medical Officer and Founder of Curadh MTR, will lead a seminar titled Optimizing Clinical Design to Ensure Patient Safety in Radiopharmaceutical Development. Reflecting on her recent presentation at the World Astatine Community Meeting, she noted, “Astatine’s short 7.2-hour half-life provides significant advantages over other radioisotopes, notably reducing radiation exposure for patients, caregivers, and healthcare personnel.”
Commenting on the collaboration, Glenn Kazo, CEO of Curadh, said, “Alpha Fusion is currently the only company worldwide with multiple At-211-based therapies in clinical trials. We’re eager to deepen our partnership, building on the impressive work led by Dr. Watabe and the Alpha Fusion team in Japan.”
こちらもお読みください： COSMOS taps RELEX to optimize supply chain and growth
Dr. Tadashi Watabe of the University of Osaka’s Graduate School of Medicine recently shared promising Phase I clinical trial results at the SNMMI. The trial led by investigators showed that At-211 is both tolerable and effective for patients with thyroid cancer who resist radioiodine therapy.
“At-211 is moving forward fast in clinical development, so we’re excited to grow in U.S. and global markets,” said Sunao Fujioka, CEO of アルファ・フュージョン.「とのパートナーシップ キュラド, combining their deep radiopharmaceutical expertise with Alpha Fusion’s platform, is instrumental in driving this growth.”
日本語